280 filings
Page 3 of 14
SC TO-T
wcrao ydxftw1
1 Dec 22
Third party tender offer statement
6:06am
SC 13D/A
ylqrp
21 Nov 22
Oyster Point Pharma / New Enterprise Associates 14 ownership change
1:29pm
SC14D9C
c7f 6by5sxt
16 Nov 22
Written communication relating to third party tender offer
4:24pm
SC TO-C
wbn7sb 4hda4049b
14 Nov 22
Information about tender offer
8:09am
8-K
uliy2wli
10 Nov 22
Oyster Point Pharma Reports Third Quarter 2022 Financial Results and Recent Business Highlights
4:08pm
SC14D9C
u0hh1
8 Nov 22
Written communication relating to third party tender offer
5:22pm
8-K
2ltfb6633 5y
8 Nov 22
Entry into a Material Definitive Agreement
5:20pm
SC TO-C
lz828yl rxegmab3v
8 Nov 22
Information about tender offer
6:06am
SC TO-C
b3qk4us omn
7 Nov 22
Information about tender offer
5:26pm
SC14D9C
wptc3ibx
7 Nov 22
Written communication relating to third party tender offer
5:23pm
SC14D9C
tkklm 1jmn0w
7 Nov 22
Written communication relating to third party tender offer
10:00am
8-K
elz 1v3jzzujgb90
7 Nov 22
Oyster Point Pharma, a Leading Ophthalmology-Focused Biopharmaceutical Company, to be Acquired by Viatris
8:15am
8-K
7z5qond
11 Aug 22
Oyster Point Pharma Reports Second Quarter 2022 Financial Results and Recent Business Highlights
4:03pm
SC 13G
b1c8f67
18 Jul 22
Oyster Point Pharma / Paradigm Biocapital Advisors ownership change
4:24pm
8-K
wl3xfjt8i2t8m qovr7t
12 Jul 22
Departure of Directors or Certain Officers
4:45pm
4
apb62y6q5o63gs2pe7
8 Jul 22
Oyster Point Pharma / Daniel Lochner ownership change
4:55pm
4
gdyt36p
8 Jul 22
Oyster Point Pharma / Jeffrey Nau ownership change
4:54pm
8-K
wbu886gnh9 jl
28 Jun 22
Oyster Point Pharma Announces Operating Expense Streamlining Plan
5:28pm